Reverse DCF
What growth does the market imply for PPLPHARMA?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
13.9% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹168
Historical Growth
3.1%
FCF Yield
3.42%
Price / FCF
29.2x
Plain English
To justify today's price of ₹167.89, PPLPHARMA.NS needs to grow its free cash flow at 13.9% per year for the next 10 years. That is 10.9% faster than its historical growth rate of 3.1%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 3.1% | ₹53 | -68.6% |
| Half implied | 7.0% | ₹83 | -50.4% |
| GDP rate | 10.0% | ₹115 | -31.8% |
| Implied | 13.9% | ₹168 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 3.1% growth, the model values PPLPHARMA at ₹53, below today's ₹168.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.